Full View

Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF

S Selvaraj, Z Fu, P Jones, LC Kwee, SL Windsor… - Circulation, 2022 - Am Heart Assoc
Background: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients
with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of …
被引用次数：57 相关文章

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF

S Selvaraj, Z Fu, P Jones, LC Kwee, SL Windsor… - Circulation, 2022 - profiles.wustl.edu
Background: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients
with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of …

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.

S Selvaraj, Z Fu, P Jones, LC Kwee, SL Windsor… - Circulation, 2022 - europepmc.org
Background Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients
with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of …

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF

S Selvaraj, Z Fu, P Jones, LC Kwee, SL Windsor… - …, 2022 - ingentaconnect.com
Background: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients
with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of …

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF

S Selvaraj, Z Fu, P Jones, LC Kwee… - …, 2022 - scholarlycommons.henryford.com
Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are foundational therapy
in patients with heart failure with reduced ejection fraction (HFrEF), yet underlying …

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF

S Selvaraj, Z Fu, P Jones, L Kwee, S Windsor… - Circulation, 2022 - avesis.tedu.edu.tr
© 2022 Lippincott Williams and Wilkins. All rights reserved. Background: Sodium-glucose
cotransporter-2 inhibitors are foundational therapy in patients with heart failure with reduced …
[HTML] nih.gov

[HTML][HTML] Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF

S Selvaraj, Z Fu, P Jones, LC Kwee, SL Windsor… - Circulation, 2022 - ncbi.nlm.nih.gov
Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are foundational therapy
in patients with heart failure with reduced ejection fraction (HFrEF), yet underlying …

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF

S Selvaraj, Z Fu, P Jones, LC Kwee, SL Windsor… - Circulation, 2022 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> Sodium-glucose cotransporter-
2 inhibitors are foundational therapy in patients with heart failure with reduced ejection …

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF

S Selvaraj, Z Fu, P Jones, LC Kwee… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients
with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of …

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF

S Selvaraj, Z Fu, P Jones, LC Kwee… - …, 2022 - utsouthwestern.elsevierpure.com
Background: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients
with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of …